Published in Medical Letter on the CDC and FDA, February 26th, 2006
The CE Mark indicates that the product complies with E.U. safety, environmental, and quality standards and makes the product eligible for sale in the E.U. NicAlert previously received clearance from the U.S. Food & Drug Administration for determining smoking status for medical uses in the U.S. Nymox has satisfactorily completed the testing and registration required to obtain CE Marking for the NicAlert test.
NicAlert uses Nymox's patented technology to provide an easy-to-use, on-site visual read-out of an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.